PATENT CLAIM ANALYSIS

Application Number: 16194486
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-03
Patent Classification: ["546", "309000"]

Abstract:
A polymorph III of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-[4-(2-methylpropoxy)phenylmethyl]urea tartrate, a preparation method therefor, and a medicinal use. Compared to the existing crystalline forms, the new crystalline form has clear advantages with respect to solubility, stability and the preparation process.

Claim (Index 4):
A method of treating a dopamine receptor-related disease in a subject, the method comprising: administering to the subject a pharmaceutical composition including an effective amount of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N\u2032-[4-(2-methylpropoxy)phenylmethyl]urea tartrate crystal form III according to  claim 1 , wherein the dopamine receptor-related disease includes mental illness, neurodegenerative diseases, dyskinesia, dystonia or thrombosis.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 98.0
- Lexical Diversity: 1.34884
- Patent Class: 546.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['11235558', '13081427', '11235381', '12795547', '11749115']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7763801446796965
- 35 USC 102 Novelty (BERT): 0.5290673206399759
- Combined Prediction Score: 0.7516488622757245
- Mean Citation Score: 308.932324
- Max Citation Score: 368.34082
- Similarity Product: 229.5022909461356

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test